Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation beads plus immunotherapy: a new hope for inoperable bile duct cancer?

NCT ID NCT06058663

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether combining a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (durvalumab and tremelimumab) is safe and shows promise for people with bile duct cancer that cannot be removed by surgery. The study will enroll 16 adults with locally advanced or limited metastatic disease. The main goal is to check for side effects, while also looking at how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Yttrium-90 (Y90) radioembolization beads, durvalumab, and tremelimumab
What this could lead to
If successful, this combination could offer a new treatment option for people with bile duct cancer that cannot be surgically removed.
What could go wrong
This is a very early Phase 1 trial with only 16 participants, so it is primarily testing safety. The treatment may not shrink tumors or improve survival, and side effects from radiation and immunotherapy could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA OLIGOMETASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 STAGE IV INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.